-

WORX FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Reminds SCWorx Corp. Investors of Important June 29 Deadline in Securities Class Action – WORX

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of SCWorx Corp. (NASDAQ: WORX) between April 13, 2020 and April 17, 2020, inclusive (the “Class Period”), of the important June 29, 2020 deadline in the securities class action. The lawsuit seeks to recover damages for SCWorx investors under the federal securities laws.

To join the SCWorx class action, go to http://www.rosenlegal.com/cases-register-1848.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) SCWorx’s supplier for COVID-19 tests had previously misrepresented its operations; (2) SCWorx’s buyer was a small company that was unlikely to adequately support the purported volume of orders for COVID-19 tests; (3) as a result, SCWorx’s purchase order for COVID-19 tests had been overstated or entirely fabricated; and (4) as a result of the foregoing, defendants’ positive statements about SCWorx’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 29, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1848.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney advertising. Prior results do not guarantee a similar outcome.

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Rosen Law Firm

NASDAQ:WORX

Release Versions

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Social Media Profiles
More News From Rosen Law Firm

Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) resulting from allegations that ImmunityBio, Inc. may have issued materially misleading business information to the investing public. So What: If you purchased ImmunityBio, Inc. securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc...

Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026. Atara describes itself as a company that “develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 8...

Rosen Law Firm Urges Coty Inc. (NYSE: COTY) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Coty Inc. (NYSE: COTY) between November 5, 2025 and February 4, 2026. Coty describes itself as a company that “together with its subsidiaries, manufactures, markets, distributes, and sells branded beauty products worldwide.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Ros...
Back to Newsroom